Biblio

Export 4 results:
Author Title [ Type(Asc)] Year
Filters: Author is Lu, Ming  [Clear All Filters]
Journal Article
M. D. Devous, Fleisher, A. S., Pontecorvo, M. J., Lu, M., Siderowf, A., Navitsky, M., Kennedy, I., Southekal, S., Harris, T. S., and Mintun, M. A., “Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1091-1104, 2021.
M. Brody, Liu, E., Di, J., Lu, M., Margolin, R. A., Werth, J. L., Booth, K., Shadman, A., H Brashear, R., and Novak, G., “A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1509-1519, 2016.
A. Russu, Samtani, M. N., Xu, S., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S., Liu, E., H Brashear, R., Styren, S., and Hu, C., “Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.”, J Alzheimers Dis, vol. 53, no. 2, pp. 535-46, 2016.
T. G. Beach, Maarouf, C. L., Intorcia, A., Sue, L. I., Serrano, G. E., Lu, M., Joshi, A., Pontecorvo, M. J., and Roher, A. E., “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.